Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HNF4A | P41235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12588926 | 0.89 | KMT2A (0.35) | KMT2AMAPTKDM4EALDH1A1NPSR1 | |
| SCHEMBL12588934 | 0.86 | KDM4E (0.33) | KMT2AMAPTKDM4EALDH1A1NPSR1 | |
| SCHEMBL2635017 | 0.83 | HNF4A (0.40) | KMT2AMAPTTSHRKDM4EALDH1A1 | |
| SCHEMBL12588944 | 0.76 | KDM4E (0.33) | KDM4E | |
| SCHEMBL17797152 | 0.74 | ABCG2 (0.37) | KMT2AMAPTKDM4EALDH1A1NPSR1 | |
| SCHEMBL17797149 | 0.74 | AHR (0.37) | KMT2AMAPTHNF4A | |
| SCHEMBL14382011 | 0.72 | KDM4E (0.34) | KMT2AMAPTTSHRKDM4EALDH1A1 | |
| SCHEMBL17797151 | 0.72 | ABCG2 (0.35) | KMT2AMAPTALDH1A1NPSR1HNF4A | |
| SCHEMBL11988006 | 0.70 | ALDH1A1 (0.35) | KMT2AMAPTTSHRKDM4EALDH1A1 | |
| SCHEMBL26935816 | 0.69 | CYP1A2 (0.31) | KMT2AMAPTKDM4EALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964743-B2 | Catalyst for asymmetric synthesis, ligand for use therein, and process for producing optically active compound through asymmetric synthesis reaction using them | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-06-21 | — | — | US | disclosed |
| US-7964743-B2 | Catalyst for asymmetric synthesis, ligand for use therein, and process for producing optically active compound through asymmetric synthesis reaction using them | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-06-21 | — | — | US | disclosed |
| US-20090156849-A1 | Catalyst for Asymmetric Synthesis, Ligand for Use Therein, and Process for Producing Optically Active Compound through Asymmetric Synthesis Reaction Using Them | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156849-A1 | Catalyst for Asymmetric Synthesis, Ligand for Use Therein, and Process for Producing Optically Active Compound through Asymmetric Synthesis Reaction Using Them | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1854802-A1 | CATALYST FOR ASYMMETRIC SYNTHESIS, LIGAND FOR USE THEREIN, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND THROUGH ASYMMETRIC SYNTHESIS REACTION USING THEM | Japan Science and Technology Agency (JP) | 2007-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156849-A1 | Catalyst for Asymmetric Synthesis, Ligand for Use Therein, and Process for Producing Optically Active Compound through Asymmetric Synthesis Reaction Using Them | ME1, ATIC, ADH1A | KMT2A 3016/4885MAPT 4330/4885TSHR 1637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.